Reviewed September 21, 2026 · For B2B procurement and development teams
A smart pen used in a clinical investigation must be fit for the study’s context of use. Event definitions, validation, participant usability, data completeness, security and operational support should be planned before the device is deployed.
Key parameters to define
- Study context of use and endpoint role
- Defined digital measure and event semantics
- Device and software version control
- Participant and site usability
- Missing, duplicate and edited data rules
- Privacy, consent and data-access responsibilities
- Provisioning, support and replacement workflow
Start with the context of use
State the study question and exactly how pen-derived data will contribute. A device used only to support participant reminders has a different evidence burden from one used to measure protocol adherence, provide an exploratory endpoint or support a primary analysis. Define the participant population, environments, study duration, countries, therapy workflow and whether the device is sponsor-provided or brought by the participant. Then define the digital measure: what physical event is sensed, how it is transformed into a record and what conclusion the study will draw. FDA guidance on digital health technologies emphasizes fitness for purpose in the specific clinical investigation. A commercial smart-pen feature should not be assumed to be suitable for trial decision-making without this context and validation. Document the decision, evidence status, responsible owner and unresolved assumptions so later project changes can be reviewed against a stable baseline.
Protect interpretability and data integrity
The data plan should describe timestamps, device identifiers, units, prime or test events, incomplete actions, manual entries, edits, duplicates, missing records and synchronization status. It should identify the authoritative source and preserve relevant audit information. Verification should cover the expected dose range, device variants, phones or readers, networks, operating systems and environmental conditions. Validation should support the intended interpretation in the study population and setting. Sponsors also need rules for device replacement, account recovery, time-zone changes, lost phones, disconnected use and participants who use an additional injection method. Security and privacy controls must align with informed consent and the parties that can access the data. Write acceptance criteria before testing so observations remain traceable to an approved requirement rather than being interpreted only after the result.
Design the operational support model
Trial deployment requires provisioning, labeling, participant and site training, help-desk procedures, replacement stock, software-version control, connectivity support, data review and issue escalation. The protocol and statistical plan should address expected missingness and technical failures rather than assuming continuous perfect capture. Decide whether participants may see or act on the data, whether reminders could influence behavior, and how software changes during the study will be controlled. Contracts should assign responsibilities among the sponsor, device supplier, app or cloud provider, sites and data-management organization. A feasibility pilot can expose workflow and data-quality problems before enrollment scales. The strongest trial solution is not the one with the most features; it is the one whose measurements and operations are controlled for the intended analysis.
Related technical paths
Connected Pen Data Guide · Cybersecurity Checklist · Discuss a Trial Device Brief
Sources and verification
Use the primary sources below to verify the current requirement and its scope. Requirements can change by device, role, market and version; this guide was reviewed on September 21, 2026.
- FDA — Digital Health Technologies for Remote Data Acquisition
- FDA — Digital Health Technologies for Drug Development
Questions buyers also ask
Not automatically. Fitness for the study context, validation and operations must be evaluated.
Only if the event definition and evidence support the study’s intended interpretation.
Yes. Storage, synchronization, missingness and recovery can materially affect trial data.
The sponsor and technology parties should define version control and change assessment in advance.
Yes. It can reveal usability, connectivity, support and data-quality problems before larger enrollment.